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ABSTRACT 
Prostate cancer (PCA) is a complex malignancy that needs to be more thoroughly studied 
and understood at a molecular level to fill the current knowledge gap, and optimize diagnosis and 
to treatment. Prostate specific antigen (PSA) showed to be not specific for PCA, therefore a 
demand for novel specific biomarkers exists. The aim of our work was to identify new specific 
candidate biomarkers for PCA in tissue and plasma samples by means of affinity proteomics 
approaches such as reverse phase protein array and antigen arrays. Tissue samples are an 
invaluable source of biomarkers for cancer, but very limited in amount and requiring invasive 
procedures for collection. Still, they allow to directly profiling the molecular status of tumor 
itself. Beside tissue, a screening procedure on biological fluid such as plasma would be highly 
desirable, thanks to the less invasiveness and low-costs of samples collection. Among the 
biomarkers detectable in plasma are the autoantibodies. The first part of this thesis summarizes 
the current status of PCA epidemiology, treatment, and biomarkers research. Beside this, an 
overview of the affinity proteomics platforms available for biomarkers research, and the critical 
variables to consider in the biomarkers validation process are presented. The second part of the 
thesis reports the main results of two original studies where the author of the thesis is the main 
contributor. Paper I is based on the profiling of PCA tissue samples using RPPA. Our results 
indicate the feasibility of combining laser capture microdissection (LCM) and RPPA for 
evaluating the molecular architecture and cross-talking of epithelial and stromal compartments. 
Paper II is based on profiling the autoimmune response to PCA patients, comparing early and late 
stage of the disease. The authors identified and characterized the IgG reactivity toward a novel 
epitope for the candidate biomarker prostein. The data presented in this thesis provide two robust 
frameworks based on affinity proteomics platforms applied for protein profiling in tissue, and 
autoantibodies profiling in plasma in the context of PCA biomarkers discovery.  
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1. Prostate Cancer: biology, epidemiology and 
treatment 
The human prostate is a walnut-sized exocrine gland of the male reproductive system. Its 
function is to produce alkaline substances that constitute the 30% of the semen volume and 
have the function to protect and prolong lifespan of sperm1. Anatomically, prostate can be 
subdivided into three morphologically distinct regions: the peripheral zone, the transition 
zone and the central zone. Benign prostatic hyperplasia (BPH) is a non-malignant growth, 
which commonly involves the transition zone in aging men. This zone surrounds 
the urethra as it passes through the prostate, and makes up about 20% of the prostate gland 
until the age of 40. On the other hand, prostate cancer (PCA) is a malignant growth that 
arises primarily from the prostate gland epithelial cells of the peripheral zone, and is 
therefore described as an adenocarcinoma 2-4 . The current PCA carcinogenesis model is 
based on a multistep process involving pre-neoplastic disorders. An initial inflammatory 
insult leads to proliferative inflammatory atrophy (PIA). PIA was then shown to merge 
with areas of prostatic intraepithelial neoplasia (PIN) and cancer tissue, providing 
evidences for the existence of a field cancerization effect and a step-wise progression5. 
According to the last data from the World Health Organization (WHO), PCA is the 
second cancer in men for incidence and the fifth cause of death by cancer in men 
worldwide, representing a public health burden6. However, the incidence of PCA 
worldwide is not homogeneous and its specific geographic and temporal patterns are still 
under study. Data from 2012 report an incidence-rate variation of 25-fold worldwide, with 
the highest rate in countries at higher socio-economical development7. In general, while 
PCA incidence has increased over time, cancer mortality has decreased, even though with 
relatively less variation and except for Africa where the highest rate of mortality is 
reported8. However, the described geographical and temporal distribution of PCA 
incidence most likely reflects the widespread of clinical practices such prostate specific 
antigen (PSA) testing and biopsy, rather than a real difference in incidence9.  
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Age remains the main risk factor predisposing to PCA, which rarely occurs before 
50 years and is more frequently diagnosed among men aged 65 and 74 with a median of 66 
years 10. Besides age and socio-economical situation, other established risk factors 
predisposing to PCA are familiarity 11, the presence of genetic polymorphisms and 
mutations 12, a fat-rich diet13, 14, and low testosterone concentration in serum 15. PCA 
incidence also varies by race and ethnicity, with the highest risk rate reported in black 
men. The reason is not yet fully understood, even though it is probably related both to 
genetic influences 16, and socio-economical reasons 17, 18.  
PCA still remains a mostly indolent disease, with only 8% of the cases becoming 
clinically apparent19 and almost 100% of them reaching the five-year survival rate when 
the disease is at local and regional stage; on the contrary, the survival rate falls to 30% in 
case of aggressive form with distant metastasis (e.g. bones, liver, brain, and lung) and 
relapse after treatment7. 
The current Food and Drug Administration (FDA) guidelines for the diagnosis of 
PCA recommend testing PSA concentration in blood, and digital rectal exploration (DRE) 
for men over 50 years of age. This well established screening practice is responsible for 
the improvement in early PCA diagnosis and the lowering of mortality rate, yet it is not 
free from drawbacks. In fact, the low specificity of PSA as a PCA biomarker, which is 
shown to increase also in prostatitis or BHP20, requires further more invasive exams such 
as biopsy to exclude false positives. Beside this, false negatives also represent an issue; it 
was reported that the 15% of PCA patients with a Gleason score of 7 or higher have PSA 
level of 4 ng/ml or lower and are negative for DRE 20. For these reasons, the role of PSA in 
PCA diagnosis has become controversial, and the existing data suggest it should be 
considered more as a prostate volume indicator rather than a biomarker of malignancy.  
Besides the urgency for an early and specific PCA diagnosis, the disparity between 
the incidence and mortality rate highlights the importance to adequately stratify PCA 
patients and distinguish the aggressive forms from the indolent forms, that is to optimize 
treatment for the firsts and avoiding overtreatment of the latters. Currently used prognostic 
indicators for PCA are the classical TNM staging system21, based on disease localization 
and spreading status, and the Gleason-grading method, which estimates tissue 
differentiation and histological pattern of cells differentiation22. Five basic Gleason grades 
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are used to generate a histological score ranging from 2 to 10, where a higher score 
correspond to cancer undifferentiation. Gleason grade has also been linked to clinical 
endpoints, such as clinical stage, progression and survival. Gleason grading of PCA needle 
biopsies is routinely used to plan patient management and prediction of response to 
radiotherapy and surgery. 
To date, therapeutic approaches are defined dependently on PCA stage, Gleason-
grading and on the age of the patient23, 24. For low grade PCA (<7) the first stratification of 
patients for treatment is based on age. Men aged above 70 with low Gleason score are 
routinely followed-up with watchful-waiting as standard-of-care approach, together with 
periodic PSA level checking, DRE and, when necessary, new biopsies. For younger 
patients with low Gleason score, prostatectomy is the treatment of choice thanks to the 
better outcome of the procedure, though is often accompanied by heavy side-effects like 
incontinence and impotence. The standard treatment for aggressive disease, independently 
of age, involves radical prostatectomy, hormonal therapy, radiation, chemotherapy, 
ultrasound treatment (HIFU) or cryosurgery. Regression is reported in 75% of the patients 
following surgery and pharmacological castration. However, the possible insurgence of a 
wide number of side effects such as osteoporosis, cognitive decline, cardiovascular 
morbidity, obesity, fatigue, and sexual dysfunctions, should be considered before therapy 
administration. Despite the development of differentiated treatment guidelines for high and 
low PCA grade, so far research has not been able to identify specific biomarkers able to 
complement Gleason scoring and improving the accuracy of PCA aggressiveness 
prediction. In fact, Gleason scoring proved to be effective for predicting the outcome and 
define the best treatment for the majority of PCAs with scores <6 and > 7, but it is poorly 
indicative for PCAs with Gleason 6 and 7, which are characterized by a largely 
unpredictable outcome.  It is not unusual that PCAs with Gleason scores <6  progress 
towards aggressive disease, and in the same manner Gleason >7 can present with indolent 
disease. Another major concern in PCA treatment is the insurgence of androgen 
independency after 12–15 months from the beginning of the ablation therapy, which could 
lead to Androgen-independent PCA (AIPC) developing by clonal selection of 
hypermutated cells after the therapy. No treatment is currently available for AIPC which is 
usually characterized by a fatal outcome.  
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As for many other types of cancer, cellular heterogeneity found in PCA represents 
a challenge for treatment and diagnosis. It is widely accepted that PCA contains 
subpopulations of cells resistant to treatments that can be the initiators of metastasis25, 26. 
Notably, metastatic PCA cells showed both inter- and intra-individual genotype and 
phenotype variations 27, and genetic heterogeneity can be traced already in the primary 
carcinoma, as shown by deep molecular profiling 28. Although not associated with a high 
mortality rate, PCA is a complex malignancy that needs to be more thoroughly studied and 
understood at a molecular level to improve on the currently available diagnostic and 
treatment strategies. The aim of our work was to identify new specific biomarkers for PCA 
by means of affinity proteomics approaches that will be discussed in details in the 
following sections. 
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2. The Proteome as a Source of Biomarkers 
2.1 Proteins, Proteome and Proteomics 
Since the Central Dogma of the Molecular Biology was stated by Francis Crick in 
195329, enormous progress was made in our understanding of the genetic information flow 
from DNA to proteins in biological systems. The Human Genome Project (HGP) was 
launched in 1990 and completed in 200330, on the 50th anniversary of the DNA structure 
discovery by James D. Watson and Francis Crick.  For the first time, the complete genetic 
blueprint that builds a human being, named genome, was fully readable. This opened the 
era of genomics, as the discipline that sequence, assemble, and analyze the genome 
structure and functions. To date, the Ensemble Database-version 86 counts 20,441 protein-
encoding genes in the human genome. Each of these genes can give rise to several protein 
variants due to genomic recombination, open reading frames, and alternative splicing 31, 32. 
DNA and genes contain all the genetic instructions for organisms’ development and 
functioning but proteins are the true functional units of the cell. Proteins participate in all 
cellular processes from biochemical reactions to cell structure, and inter-cellular cross-
talking. Their active or inactive status is dictated by post-translational modifications 
(PTMs)33. PTMs are chemical modifications that occur after protein translation, such as 
glycosylation, phosphorylation, ubiquitination, methylation, nitrosylation, 
acetylation, lipidation and proteolysis. PTMs can occur in every phase of the life of 
a protein. Moreover, whereas genetic mutations can only occur once per position, 
different PTMs may occur in tandem. PTMs are most often mediated by enzymes such as 
kinases, phosphatases, transferases and ligases, which add or remove functional groups, 
lipids or sugars to or from amino acid side chains, and proteases, which cleave specific 
sequences or regulatory subunits. Beside this, autocatalytic domains also allow proteins to 
self-modify. 
The total complement of proteins present in a cell is known as its proteome, and the 
discipline that has the aim of deciphering it is known as proteomics.  
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The human proteome is incredibly complex and dynamic (Fig. 1). Proteins interact 
with other proteins and are organized in pathways and networks that regulate all cell 
functions and processes, from duplication to death. Indeed, protein-protein interactions are 
responsible for triggering signal transduction cascades to respond to stimuli coming from 
inside or outside the cell, and cause modifications of cellular processes.  Networks of 
proteins adapt in response to multiple concomitant stimuli, determining an 
observable phenotype. Pathological phenotypes appear when variations occur at genetic, 
translational or post-translational level, determining an alteration in protein expression, 
conformation or activation that interferes with the normal interaction with other proteins. 
Indeed, beside the central dogma of the molecular biology, a new paradigm has 
been recently introduced where network biology or system biology represents the 
conjunction between genotype and phenotype34.  
 
 
Figure 1. Complexity of the human proteome. While the genome counts around 
20000 genes, the human proteome is estimated to be composed by over 1 million 
proteins. Changes at gene levels and different ORFs cause the production of 
many different transcripts from a single gene. At a post-traslational level are the 
PTMs that represent the major source of protein diversity. 
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PTMs are key regulators of protein-protein interaction or protein-biomolecules 
interaction, representing the base of signal transduction. Identifying and understanding 
PTMs is a critical step in the study of cell biology and disease diagnosis, treatment 
and prevention. Based on previous estimates, it is widely believed that the most 
abundant PTM is glycosylation. However, phosphorylation has a leading role as 
controller for the kinome and its aberrant activation in human cancers 35-37. The vast 
majority (90%) of protein phosphorylation occurs on serine and threonine residues, while 
only 10% occurs on tyrosine. Growth factor signaling starts from tyrosine kinase receptors 
(e.g. EGFR, HER2 and VEGFR), which after binding to the ligand, dymerize and 
autophosphorylate, and trigger a cascade of events resulting in further interactions with 
downstream kinases 38-41.   
Proteomics and its branches (e.g. phosphoproteomics) have a foreground role in 
clarifying molecular processes underlying normal and disease status, therefore 
representing an invaluable tool for the development of diagnostic, prognostic, therapeutic, 
and preventive medical applications. In 2010 Human Proteome Organization (HUPO) 
started an international effort named Human Proteome Project (HPP; 
http://www.thehpp.org/). The HPP mission is to generate the map of the human proteome 
and to become a source to help elucidating biological and molecular function, and 
improving diagnosis and treatment of diseases. Many research laboratories around the 
world participate in the project, which still represents a challenge in life science. Emerging 
technologies based on mass spectrometry (MS) and affinity proteomics are applied to 
reach this goal. The Human Protein Atlas (HPA) project is part of this effort, and aims to 
map the spatial distribution for the whole human proteome in tissues and cell lines by 
means of antibodies. Part of the work presented in this thesis is based on data generated by 
using antigen arrays obtained from the HPA. Further details about HPA are discussed in 
paragraph 3.1.1. 
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2.2 Protein Biomarkers for cancer and personalized 
medicine 
 
The National Institute of Health (NIH) defines a biomarker as “a biological 
molecule found in blood, other body fluids, or tissues that is a sign of a normal or 
abnormal process, or of a condition or disease.” Additionally, “A biomarker may be used 
to see how well the body responds to treatment for a disease or condition”. All kind of 
biomolecules (e.g., proteins, nucleic acids, antibodies, peptides, etc.) can serve as 
biomarkers42 but, as previously stated, proteins represent the best indicator to monitor a 
biological status or response to stimuli, therefore representing the ideal candidates for 
biomarkers.  
A protein biomarker is a protein that can be measured in body fluids or tissues, and 
reflects a certain status of an individual.  Protein biomarkers for cancer can be divided into 
diagnostic, prognostic, and predictive43. Diagnostic biomarkers are used to detect a disease 
in an individual, while prognostic biomarkers are helpful in defining the disease 
progression, aggressiveness and recurrence. Predictive biomarkers are useful after 
diagnosis, and allow selecting the optimal treatment by stratifying patients based on their 
responsiveness or non-responsiveness.  
Proteins are the direct targets of new personalized treatments. The main targets of 
currently FDA approved monoclonal antibodies are kinases or proteins belonging to the 
signaling networks involved in cancer cells survival, proliferation and migration44. The 
activation or inhibition of a protein kinase gives rise to a cascade of events that modify the 
status of a pathway, or of the entire protein network modulating cellular status and 
processes 45. As above mentioned, mapping the proteomic and phosphoproteomic network 
is fundamental to have a clear picture of the status of a cell and tissue.  
Tissue samples are invaluable source of cancer biomarkers, even though they are 
very limited in amount and requiring invasive procedures for collection.  To overcome 
these limits, a screening procedure based on biological fluid testing (e.g. plasma, serum, 
urine, saliva) would be highly desirable, due to the possibility of collecting much higher 
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volumes, with less invasiveness and low-costs. Biological fluids are not just practically 
convenient; they represent a real important source of proteins deriving from tissues by 
secretion, or released as a consequence of tissue damage or molecular changes related to a 
disease, included cancer. Disease conditions can deregulate the conventional processes of 
protein translocation and secretion, determining changes of protein levels in body fluids 
that do not necessary reflect an aberrant expression of the same protein at the tissue level. 
Such variation in protein levels into the circulation is therefore not predictable from tissues 
analysis alone. Yet, a mutated form of a protein – either at translational or post-
translational level - may be expressed by tumor tissue at different levels compared to the 
normal tissue, but with a negligible resultant increment in the circulating level due to the 
greater mass of unaffected tissue releasing the native protein.  
Autoantibodies, produced by the organism to recognize tumor-associated antigens 
(TAAs), are particularly notable amongst serological cancer biomarkers 46 and recently the 
scientific community invested a lot of effort in correlating their expression with clinical 
parameters, thus demonstrating their usefulness in diagnostic and prognostic processes47. 
It is easy to understand that an ideal protein cancer biomarker should originate 
from the affected tissue, be present with detectable concentrations in body fluids, correlate 
with the disease severity, and specific for the considered cancer type, with high sensitivity 
(low rate of false negatives) and high specificity (low rate of false positives)48. All these 
requirements are unlikely to be fulfilled by a single protein; beside this, the complexity of 
cancer also suggests that a panel-of-biomarkers would be more effective.  
Proteomics and phosphoproteomics demonstrated to be highly promising for 
biomarkers discovery. The continuous technological improvement (e.g. throughput, 
multiplexing and sensitivity) have allowed the detection and quantification of proteins in 
many different body fluids and in tissue49, 50. The biomarker pipeline is commonly 
constituted by a series of preclinical phases (e.g., biomarker discovery, verification, 
evaluation) followed by a final clinical evaluation (Paulovich et al., 2008; Rifai et al., 
2006; Rodriguez et al., 2010a; Surinova et al., 2011). Through this process, biomarkers are 
“filtered”. Hundreds or thousands of targets are analyzed in only few samples at earlier 
phases, while a handful of targets are measured in thousands of samples at late phases (Fig. 
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2). An appropriate proteomic platform has to be chosen for each phase, based on 
throughput and multiplexing capability. 
 
 
Figure 2. Biomarkers discovery and implementation into clinics. The diagram summarize the four phases 
in which the process from candidate biomarker discovery to implementation into clinics, passing through 
verification and validation. 
 
During the last 15 years, thousands of potential protein biomarkers for cancer and 
other diseases have been published. However, some major challenges including pre-
analytical, analytical, and post-analytical variables still represent a barrier to biomarkers 
validation and introduction in the clinical practice and personalized cancer treatment 51. 
We will discuss these aspects in details in the following sections of this thesis.  
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3. Affinity Proteomics in Biomarkers Discovery 
and validation  
 
3.1 Affinity Proteomics for a proteome-wide analysis 
 
From a technological point of view, proteomics can be subdivided into two main 
branches. Mass-spectrometry (MS)-based proteomics and affinity-based proteomics 
represent two alternatives for approaching a proteomic question. MS has become the gold 
standard for analysis of complex protein samples, thanks to the availability of gene and 
genome sequence databases, and most notably thanks to the development of protein 
digestion and ionization methods which led to the 2002 Nobel prize in chemistry52, 53. 
Affinity proteomics, instead, is the field of proteomics based on the use of antibodies and 
other binding reagents as protein-specific detection probes49, 54. The two merge in immune-
MS, which couple the selectivity of affinity enrichment to the certain protein identification 
provided by MS. This approach is promising in the detection of low-abundance protein 
biomarkers55 and in the study of protein-protein interaction (PPI)56. However, MS is not 
exempt drawbacks, such as low throughput and sensitivity, and high costs. 
In the medical area, affinity proteomics plays an important role in the identification 
of biomarkers, as well as for identifying new drug targets49. Affinity proteomics 
performance depends strictly on the availability of specific binders, and an availability of 
sensitive and high throughput detection methods. 
Several different types of affinity reagents are available, but antibodies are still the 
most commonly used tools in affinity-based assays. Despite the commercial availability of 
around 2,000,000 antibodies, only 500,000 are unique and in many cases characterized by 
a variable quality. Published data report that the 25% of the commercially available 
antibodies fail specificity and are inconsistently performing across different application57, 
though forcing each laboratory to run validation tests. Comprehensive resources collecting 
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quality-controlled and well-performing binders are required. Several antibody catalogues 
are available online. Antibodypedia is one such catalogue, and counts more than 1,800,000 
antibodies covering 94% of the human protein-encoding genes58. Other resources include 
Biocompare (http://www. biocompare.com/), antibodies-online (http://www.antibo dies-
online.com/) and Antibody Registry (http://www.antibodyregistry.org/). The feasibility of 
producing affinity-purified polyclonal antibodies directed toward the whole human 
proteome is represented by the HPA project (details in Paragraph 3.1.1). A major 
drawback of polyclonal antibodies is their finite availability; therefore, a big effort is now 
dedicated to the production of renewable affinity reagents, such as monoclonal antibodies, 
and recombinant affinity reagents. Among the latter we can cite antibody fragments59, 
SOMAmers60, nanobodies, camelids single-domain antibodies61, 62, and affibodies63.  The 
high cost of production still represent a barrier to the application of these affinity binders 
on a broad scale. Affinity binders can be applied to create affinity-based assays in several 
different formats. In the following sections I will discuss the two protein array formats 
applied in the work presented in this thesis: antigen arrays and reverse-phase protein array. 
 
 
3.1.1 The Human Protein Atlas Project 
 
A map of the human proteome, similar to the one for the genome, could lead to a 
better understanding of the molecular basis of diseases, fill the gap to explain complex 
pathological conditions, and improve the treatment strategy. For these reasons, large scale-
efforts primarily based on mass-spectrometry technology have been made to identify all 
the protein products deriving from the translation of the human protein-coding genes64-66. 
Beside this, in 2003, the HPA project started with the aim to produce antibodies specific 
for all the human proteins and to create an “atlas” of the human proteome across cells, 
tissues and organs 67. The atlas provides information about proteins expression and 
RNAseq data. Antibodies are produced based on a gene-centric approach. In-silico 
selected antigens, named protein epitope signature tag (PrEST), are used to immunize 
rabbits. Each PrEST consists of approximately 50-150 aminoacids and an affinity tag 
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(His6-ABP), and has <60% homology to any other human protein-encoding gene. Also, all 
transmembrane domains of proteins are not considered68, 69. After selection, the target 
region in the gene is amplified from a total human cDNA pool, cloned and expressed in 
Escherichia coli as a recombinant fusion protein. The His-tag is used for the subsequent 
purification using affinity chromatography, while the albumin-binding protein (ABP) 
confers an increased solubility and immunogenicity70, 71. The purified PrEST sequence is 
verified by mass-spectrometry analysis, and used to immunize rabbits and purify the 
generated antibody72. PrESTs are also printed onto planar arrays in randomly selected sets 
each containing 384 antigens. Planar antigen arrays are then used to verify each antibody 
target and off-target binding, to determine its specificity.  
The antibodies passing the criteria of specificity on PrEST array are then further 
analyzed in western blot using human cell line lysates, depleted plasma, as well as tissue 
lysates73. Only the antibodies confirming the presence of bands at the right molecular 
weight on western blot analysis are then utilized for protein expression profiling on human 
tissue microarrays (TMA) and human cell lines by immunohistochemistry (IHC)73, 74. 
Subsequently, the subcellular localization is evaluated on human cell lines by 
immunofluorescence (IF) and confocal microscopy75. More recently, these data have been 
supplemented with RNA-seq data from human organs and tissues 76. All the mass-
spectrometry, western blot images, IHC and IF images, and RNA-seq data are public 
available on the HPA portal (http://www.proteinatlas.org/). The current version 15 of the 
HPA has been released in April 2016 and counts 25,039 antibodies targeting 17,005 
unique human proteins, corresponding to 86% of the human protein-coding genes. 
Antigen arrays are systematically generated within the HPA, and represent also an 
invaluable tool to explore the autoantibody repertoire in body fluids with the aim to 
identify potential biomarker candidates 77. 
HPA represents a standalone resource for the scientific community, enabling 
researchers from all over world to access to a wide range of data and reagents towards 
their proteins of interest, cell lines or tissue, complementing the mass-spectrometry based 
proteome maps78. 
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3.2. Protein Arrays 
  
Historically, IHC was the first affinity-based technique to be introduced in the 
study of proteins expression. Later on, two-dimensional gel electrophoresis (2D-GE) was 
developed and allowed the study protein expression and activation status, but also 
biomarkers discovery. These approaches are based on the classical ‘one binder, one 
sample’ setup. In the last 15 years affinity-based assays have been considerably expanded 
and adapted for proteome-wide scale studies, thanks to the introduction of miniaturized 
platform named arrays, which allow high-throughput and multiplex analyses. Protein 
microarrays derive from the DNA array format as introduced by Schena and colleagues in 
199579, and later adapted to proteins. Over the past decade, protein microarrays greatly 
contributed to advances in proteomics and systems biology. They have been applied in 
numerous studies for uncovering the molecular bases of normal and pathological 
conditions, including protein-protein interaction, protein–DNA interactions, PTMs, 
signaling cascades, and pathogen–host interactions80. The great advantage of protein 
microarrays is their flexibility, which allows modulating the throughput and multiplexing. 
Several different formats of protein arrays exist81. The main distinction is based on the 
binder-sample setting. Forward phase protein array format (FFPA) is characterized by 
affinity-binders immobilized on a solid surface. Samples are usually diluted in assay buffer 
and flooded over the array, where analytes are captured by the immobilized binders. This 
assay format is characterized by medium to high multiplexing possibility, and low to 
medium throughput. FFPAs allow to test the expression pattern of up to thousands proteins 
in individual complex samples (e.g., body fluids, tissue lysate, cell line lysate) on planar 
format, or hundreds of proteins in hundreds of samples on bead format (e.g., 500 proteins 
in 384 samples using Luminex technology82). FFPA can be sub-classified based on the 
capture molecule immobilized on the solid surface (e.g., antibodies, antigens). Several 
different surfaces are available and allow the immobilization of the affinity binder while 
considering the conformational and functional characteristics that are needed for the 
analysis83, 84. Surfaces exist to guarantee the 3D conformation of antigens or proteins, or 
for directional immobilization, or adsorption. Once the analyte is captured, a detectable 
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signal is generated either by direct labeling of the sample with biotin and addition of 
streptavidin-phicoeritrine, or using a detection antibody conjugated to a fluorescent 
molecule (e.g. sandwich assay). Inversely to FPPA, Reverse phase protein array format 
(RPPA) is based on the immobilization of samples onto the array surface, and the 
following addition of capture antibodies in solution to test the expression or activation of 
specific proteins. This format allows to test up to thousands samples (high-throughput) for 
few targets (low to medium multiplexing).  
When fluorescence is used as detection system, generated signals are measured by 
laser-based systems in both FPPA and RPPA formats. Dedicated software are able to 
quantify signals and convert them into numbers, generating output matrices that are used 
for data analysis. Genepix, Microvigene and xPONENT Luminex are the 3 used for the 
work here presented. Data analysis was run using several data analysis platforms, such as 
R, Graphpad and Jump. 
A third type of array is functional array. Functional arrays are constructed with purified 
proteins, to enable testing various protein biochemical properties, such as interactions with 
proteins, nucleic acids, lipids, drugs, peptides, binding activities, and enzyme-substrate 
relationships interactions. 
 The following paragraphs describe principle and applications of antigen and 
peptide array, and RPPA. 
 
 
3.2.1 Antigen and Peptide arrays 
 
Antigen and peptide arrays are FFPA subtypes, where protein fragments or short 
peptides are immobilized on a solid surface, which can be planar or a micro-bead.  
Antigen array technology is very useful for profiling the autoantibody repertoire in 
body fluids. Part of the results presented in this thesis (Paper II) were generated using 
antigen planar arrays routinely generated within the HPA project for the antibody 
validation process 72, 85. Human protein fragments with average length of 100 aminoacids 
are immobilized onto a planar glass surface by means of non-contact printers 86. Droplets 
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of 50-500 pl of diluted antigen are needed for generating spots sizes of 100-300 mm 87.  
Planar platforms room tens-of-thousands of spots in each single slide, allowing a high 
multiplexing capability. Signal generation relies on fluorescence-based systems, where two 
secondary antibodies coupled to fluorofores are used. One antibody targets the protein 
fragment His-tag, and the resulting signal is used as quality control for antigen presence 
and spot shape. The second fluorescence conjugated antibody is an anti-human IgG, which 
generate a signal when a human antibody recognize one of the antigen printed onto the 
array.  Signals are detected by means of a dual channel fluorescence scanner system 
(Agilent G2565 array scanner). The generated image is analyzed using dedicated soft 
wares (e.g., Genepix) allowing signal quantification. Within the HPA project, three 
different configurations of planar antigen arrays are available: 384 antigens printed in 21 
sub-arrays (21 copies of the same 384 antigens collection), 11520 antigens in 2 sub-arrays, 
or 21120 antigens in 1 sub-array.  
The second available platform for antigen arrays is bead-based, called suspension 
bead array. Protein fragments are immobilized on Magplex microspheres (Luminex), 
measuring 5.6 micrometer diameter and embedded in superparamagnetic particles 88. 
Magnetic beads are very useful for assay automation, allowing automated plate washing 
and transfer, improving standardization and minimizing human errors. Microspheres are 
functionalized with carboxyl groups, which allows for covalent immobilization of the 
protein fragments via their primary amines. Luminex beads are color coded; 500 
distinguishable beads identities (IDs) are obtained by mixing 3 dyes in different 
proportions. Each ID carries a different antigen type, and IDs can be mixed to form an 
array. A signal is generated by using a fluorescence labeled anti-human IgG antibody. A 
dual laser system integrated on a flow cytometry system (Flexmap 3D) is then used to 
measure the fluorescence intensity and identify bead identity. This system allows for 
semiquantitative methods.  
Bead-based arrays are very flexible, offering the possibility to fully customize the 
array for each experiment. Another advantage is the possibility to avoid laborious image 
analysis process. However, the multiplex capability of bead-arrays is limited to the 
commercially available bead IDs, while the multiplexing capability of planar array is much 
higher. On the other hands, bead array allows a higher throughput compared to planar. 
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Planar antigen arrays can be considered as suitable for discovery studies and broad 
screenings, and antigens selected on this phase can be coupled to beads to create a targeted 
array and verify planar array results on a higher number of samples. This experimental 
design has been applied to study autoimmunity and to identify autoantibodies biomarkers 
in different type of pathology and body fluids 77, 89. 
The first applications of antigen arrays for studying autoantibodies are dated at 
beginning of 2000, when the first arrays were created to test already known autoantibodies 
90, 91. After these proof-of-concept applications, antigen arrays have been applied to several 
hypothesis-driven and hypothesis-free studies in the context of autoimmune diseases, such 
as rheumatic diseases92 and lupus erythematosus93, but also in multiple sclerosis94, 
Alzheimer’s disease95, and several types of cancer96. 
Limit of this type of array is represented by the fact that antigens represent only 
part of a protein, causing loss of information when the epitope is sited on a protein region 
not covered by the antigen, or when the epitope is conformational. Yet, the wide collection 
of antigens available within the HPA project represents a unique resource for studying 
autoimmunity.  
However, antigens reactivity does not give any precise information about the 
epitope, which can be linear or conformational, and varies a lot in dimension97. When 
studying autoantibodies as biomarkers or for the development of cancer-specific vaccines, 
it is essential to fine map the reactive epitope and define the specificity of such reactivity98. 
Autoantibodies can be directed against intracellular or extracellular autoantigens, and this 
has been noticed to relate differently with pathogenicity99. In central nervous system 
related diseases, autoantibodies targeting intracellular antigens are believed to be 
biomarkers for an underlying tumor100.  
Epitope mapping methodology involves the use of soluble and immobilized 
overlapping peptide libraries, often in an array format 101. Both planar and bead based 
formats are suitable, however bead-arrays are the method of choice when the mapping is 
related to one or a handful of short sequences (e.g., antigen). This approach can also be 
combined with alanine scanning102, in which alanine substitutions are introduced into the 
synthetic peptides, allowing the study of the contribution of each single aminoacid in 
epitope recognition. An important application for epitope mapping is the localization of 
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epitopes for commercially available antibodies. This helps in defining which antibody to 
use for which application; when an assay is based on denaturated proteins, antibodies 
detecting linear epitopes are useful, while conformational epitopes are available only for 
proteins in native conformation. Maier and colleagues 103 published a high-throughput 
epitope-mapping of the vitamin-D receptor by using a recombinant peptide library 
consisting of 2304 overlapping peptides. More recently, Forsström and colleagues104 
described, for the first time, a peptide array based on parallel in situ photolithic synthesis 
of a total of 2.1 million overlapping peptides and covering all human proteins for the 
analysis of antibody specificity. A peptide bead-array can be generated by pre-coating 
beads with neutravidine, and affinity coupling biotin-labeled peptides. The signal detection 
method and read-out are the same as reported for antigen array. Also in this case, a limit of 
this mapping technology is the application only for mapping linear epitopes. 
 
 
3.2.2 Reverse Phase Protein Microarray  
 
RPPA is a sensitive, quantitative and robust technology allowing the analysis of 
protein expression and PTMs such as phosphorylation, glycosylation, ubiquitination and 
cleavage. 
RPPA derives from miniaturized immunoassays105, and the term “reverse” is used 
to distinguish it from FFPA. Contrary to FFPA, in RPPA is the sample to be immobilized 
onto the array. RPPA was described for the first time in 2001 by Paweletz and 
colleagues106 as a powerful technology characterized by high-throughput and multiplexing 
possibility. Each array can host thousands of spots, depending on the desired dimension 
that can be set by using different array systems.  
The optimal substrate for RPPA is a nitrocellulose coated glass slide. 
Nitrocellulose has high affinity for proteins, does not change their conformation, and gives 
low background107. RPPA samples are first denatured and then printed on the slide support 
by using a solid pin-based contact arrayer. Each pin has a flat end, and dips in a different 
sample loaded into a multiwell microplate. The sample is subsequently transferred onto the 
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nitrocellulose surface by contact. Several different types of pins are available with 
different diameters108. Only few picograms of total protein are needed for each array, 
allowing to print up to hundreds of arrays with just a few microliters of sample. The total 
number of samples printed on an array depends on number of replicates, sample dilutions, 
controls, and calibrators included in a specific experimental design (Fig. 3) 109, 110.  
 
 
 
Figure 3. Reverse Phase Protein Array. A) The scheme represents the RPPA 
workflow, constituted by two main phases: the printing phase of sample onto 
nitrocellulose coated glass slides, and the immunostaining of the array with a 
primary antibody and a conjugated secondary antibody. B) Representation of 
how an RPPA slide appears after signal detection. In RPPA positive controls, 
negative controls and standard curves are always present together with unknown 
samples. All samples and standards are spotted in replicates (e.g., triplicates). 
 
 
 
Several different types of samples can be tested using RPPA, such as whole tissue 
lysates, enriched tissue lysates (e.g., microdissected tissues) 111-113, cell lysates114, 115, 
serum and plasma116, and CSF 117. Each RPPA spot represents the whole cellular 
proteome; therefore, the selection of highly specific detection antibodies is essential. 
RPPA antibodies validation is based on western blot, and only antibodies generating a 
single band at the right molecular weight are considered as validated 50. Known positive 
and negative controls (e.g., cell or tissue lysates) for expression or activation of a certain 
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protein are tested in parallel to confirm the antibody specificity for the target. 
Each array is probed with a detection antibody followed by a secondary antibody 
conjugated with enzymes.  High sensitivity is ensured by using signal amplification 
systems based either on colorimetric or fluorimetric detection118.  
RPPA allows comparing the pattern of expression and/or activation of a certain 
protein across all samples tested in the same exact condition. A laser scanner and a 
dedicated software (e.g. MicroVigene, Vigenetech) are used to reveal signal intensity for 
each spot. In parallel to technological advancement, bioinformatics tools have been 
developed for data quality assurance, normalization and quantification119. Qualitative 
evaluation of each image and spot is manually performed by the operator. The analyte 
concentration is proportional to signal intensity after subtraction of background and 
negative control signal, and normalization to total protein amount. The normalized data 
can be used to run a wide range of analysis.  
Each array reports data about expression and/or activation of a single target. 
Thanks to automatized immunostaining systems, several different arrays can be stained in 
parallel with different antibodies, allowing rebuilding the functional status of entire 
pathways driving cellular functions such as growth, survival and migration. Clarifying the 
entire cascade of events that leads to the activation and deactivation of proteins is the first 
step in identifying alterations in cell homeostasis that will drive the carcinogenesis 
processes. The great sensitivity of RPPA is a unique advantage when analyzing samples 
limited in their amount, such as needle biopsies in clinics. For this reason RPPA found 
applications in cancer-targeted therapy, but also in the assessment of treatment for other 
type of diseases, as well as for diagnostic and prognostic biomarker identification.  
When analyzing tissue samples, the coupling of RPPA with laser capture 
microdissection (LCM) showed to be very powerful. LCM allows capturing pure (e.g., 
95%) cellular populations that can be separately analyzed on RPPA for their molecular 
status. The variable composition of tissue samples can generate data misinterpretation 
when analyzing whole tissue lysates. LCM showed an invaluable tool for upfront 
enrichment of homogeneous cellular populations111. The results presented in this thesis 
(Paper I) have been generated by coupling LCM to RPPA to map the stroma-epithelium 
cross-talk. 
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RPPA can be calibrated including standard curves and internal positive and 
negative controls, allowing inter-experimental comparison and the generation of 
quantitative data120. RPPA showed to be particularly suitable for phosphoproteins 
measurements, representing a unique tool for rebuilding the activation status of key 
pathways in cancer development and progression121-123, and response to treatment124, 125. 
The great effort in technical optimization allowed RPPA to find application in several 
clinical trials. Among these are the I-SPY1 and I-SPY2 clinical trials for the identification 
of new biomarkers and optimization of personalized treatment in breast cancer. I-SPY1 
identified high levels of HER2 Y1248 in a subgroup of patients in absence of HER2 
overexpression. This group showed also hyperactivation of HER3 and EGFR, indicating 
that these patients could get advantage from HER-targeted therapies126, 127. RPPA is also 
applied within the Side-Out´s Breast Cancer clinical trial, to find potential targets and 
select individualized treatments for patients with previously treated metastatic breast 
cancer. At the date when this thesis was written, the Phase III of this clinical trial was just 
launched128.  
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4. Protein Biomarkers in Prostate Cancer 
As above mentioned, the discovery of PSA revolutionized PCA diagnostics129. 
Since the introduction of the serum PSA test in clinical practice, the diagnosis of PCA has 
become more frequent. However, 50–75% of patients with elevated PSA level have a 
negative biopsy result for PCA130. Due to this low PSA specificity, several studies aimed 
to identify novel biomarkers for PCA. 
High throughput proteomic platforms might be very promising in identifying and 
quantifying new biomarkers for PCA in body fluids and tissue131. The direct analysis of 
tissue might allow to get the molecular picture of PCA, and to uncover the processes 
leading to its genesis and progression. On the other hand, and as previously discussed, 
PCA diagnosis and treatment would highly benefit from a screening test procedure based 
on biological fluid, due to the minimally invasive, rapid and low-cost procedures needed to 
collect clinical samples. Beside plasma and serum samples, also urine, prostatic secretion 
and seminal plasma have been and keep being extensively investigated132-134. The aim of 
this paragraph is to summarize the main findings in PCA biomarkers discovery and 
validation. 
4.1 Protein Biomarkers in Tissue 
The multistep process leading to PCA through PIA and PIN pre-malignant states 
has been partially characterized and some common mutations were identified. Among 
these, PIA showed upregulation of Bcl-2 and GSTP1, and down-regulation of PTEN and 
CDKN1B. The progression to PIN is characterized by ETS transcription factor 
dysregulation and by the well-known TMPRSS2-ERG gene fusion135, 136. Later, PTEN 
deletion and RB1 loss represent key events at early phases of PCA oncogenesis 5. 
Androgens (e.g., testosterone, androstenedione and dehydroepiandrosterone) regulate PCA 
growth by both stimulating cell proliferation and inhibiting apoptosis. They are released 
into the blood flow and circulate bound to albumin or sex-hormone binding protein 
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(SHBP). Thanks to their hydrophobicity, androgens enter prostate cells, where they are 
processed to the active form (e.g., dihydrotestosterone). Active androgens bind to 
androgen receptor (AR) and cause its conformational change and activation by 
phosphorylation and homodimerization. Activated AR is then transferred into the nucleus 
where binds to promoters and starts transcription of cell growth and survival promoting 
genes, and of PSA137. Therefore, the AR is the main candidate target for PCA treatment. 
More than 600 mutations have been reported for AR gene alone and many of them 
influence AR interactome and signaling transduction138, 139. Well-differentiated low-grade 
PCA contains glandular structures with tumor cells expressing known AR and PSA, while 
poorly differentiated late-grade PCAs are lacking in glandular structures and show more 
profound changes at a molecular level2. AR signaling cascade is therefore not sufficient to 
sustain tumor growth and progression, especially in late stage PCA where the tumor 
becomes androgen independent. Paracrine mediators secreted by stroma, such as IGF, FGF 
and EGF, are responsible for tumor epithelium-stroma cross-talk and causes the activation 
of other receptor tyrosine-kinases (RTKs) (e.g. IGFR, FGFR and EGFR) which together 
with AR sustain the PCA cells survival and proliferation at late stages of the disease140, 141. 
Beside this, at late PCA stages AR can be activated through alternative pathways and in 
absence of androgens141. The ligand-independent AR activation could take place through 
the phosphorylation induced by RTKs-activated AKT or MAPK 140, the protein kinase A 
signaling 142, or by the AR-STAT3 association induced by IL-6 143. All these molecules 
involved in different stages of PCA progression are potential targets for novel personalized 
therapies. 
Tissue samples collected at all stages of PCA, from normal tissue to metastasis, 
have been profiled with the aim to identify new biomarkers. Already in 2001, Paweletz 
and collaborators demonstrated that SELDI-MS coupled to LCM enriched tissue samples 
are useful tools to analyze PCA tissue samples and to identify different molecular profiles 
from different cellular compartments (e.g., normal, tumor, invasion front)144. Later, the 
same technology combination showed that PCA-24 as an hypothetical biomarker able to 
distinguish PCA from normal tissue and BPH with high specificity and sensitivity145. 
Other studies reported signatures able to separately cluster BPH from PCA. Disulfide-
isomerase, 14-3-3-protein, enoyl CoA-hydrase, prohibitin and B-tubulin β-2 showed to be 
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increased in PCA, while Keratin-II, desmin, HSP71, ATP-synthase-β-chain and creatine 
kinase- β-chain were increased in BPH146. Quantitative mass-spectrometry identified 
periostin to be up-regulated in PCA compared to BPH147. P53, c-MYC, AR and PSA, 
resulted to be the central hubs all known to be key regulators for PCa onset and 
progression and potential targets for therapy148. 
High-grade prostatic intraepithelial neoplasia (HGPIN) is a precursor of PCA. 
From a morphological point of view HGPIN is similar to PCA, but it retains a basal-cell 
layer149. Proteomic profiling of LCM enriched tissue identified GDF15 protein expression 
in 70% of PCA, 38% of HGPIN and absent in normal tissue, suggesting its role as a 
marker of early carcinogenesis150. Basal cells have also been specifically profiled since 
they are thought to play an important role in prostate carcinogenesis process, by being the 
physical barrier for PCA invasion of the adjacent stromal compartment151, 152. Retinoic 
acid-binding protein 2 was found to be down-regulated in basal cells of benign prostate 
compared with PCA and prostatitis153. 
As above mentioned in detail, depending on the grade of invasion and cell 
morphology, PCA is classified based on Gleason scores. Matched biopsies collected from 
BPI, Gleason 6 PCA and 23 Gleason 8+ PCA, have been analyzed using LCM coupled to 
mass-spectrometry, identifying lamin A as an hypothetical biomarker of differentiation and 
prognosis154. The higher the Gleason score, the higher is the grade of tissue invasion. 
EPLIN down-regulation was found to promote epithelial-mesenchymal transition (EMT) 
in PCA, and to correlate with metastases155. Previous studies report potential biomarkers 
for the detection of lymph-node metastasis (LNM). Collapsin response mediator protein-4 
(CRPM4) was found to be a LNM suppressor156. Also a 6 protein panel (e.g., e-FABP5, 
MCCC2, PPA2, Ezrin, SLP2, and SM2) was found to be differentially expressed between 
PCA with and without LNM157. 
Variations at protein expression and activation can be due to genetic and epigenetic 
mutations. Several miRNAs participate in proteome modulation during PCA genesis and 
progression158, 159. MiRNAs are known to be involved in the regulation of AR signaling as 
well as p27160, 161.  
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4.2 Protein Biomarkers in Body Fluids 
Tumor invasion causes the destruction of tissue architecture and the release of 
proteins, first into the interstitial fluid, collected into the lymphatic system and finally into 
blood or other biological fluids, such as seminal fluid and urine. In normal conditions, PSA 
is expressed by prostatic epithelial cells and then secreted into the lumen of the gland as a 
component of seminal plasma (0.5–3.0 g/l). In PCA, the anatomic barrier between glands 
and capillary is disrupted causing PSA concentration in blood to raise from 0.5–2.0 ng/ml 
to 4–10 ng/ml in early stages of cancer, and up to 1 µg/ml in the late stages 48. Beside 
influencing intracellular proteins, pathological conditions can also cause variation in 
proteins secretion, shedding of transmembrane proteins or part-of-proteins (e.g. 
extracellular domains), and variation in the anti-tumor response (e.g. C-reactive protein, 
immunoglobulins and chemokines).  
Several studies focus on new candidate PCA biomarkers in biological fluids. A 
proteome profiling using MS of voided urine from PCA patients and individuals with 
negative biopsy allowed to identify a polypeptide panel confirming the presence of 
prostatic secretion, which can be the source of relevant prostate biomarkers in urine. These 
polypeptides resulted from Collagen α-1 (III) [642–659], Collagen α-1 (I) [699–725], and 
Psoriasis susceptibility 1 candidate gene 2 protein162 (SPR1). This panel was validated on a 
blinded set of 213 samples (118 PCA and 95 negative biopsies), showing 89% sensitivity 
and 51% specificity. When age and percentage of free PSA were added to the signature, 
sensitivity reached 91% and specificity 69%163. The panel was then evaluated on routine 
clinical application, showing sensitivity 86% and specificity 59%164.  
A profiling of PCA serum samples performed by antibody microarrays for 180 
different proteins identified five potential biomarkers (von Willebrand Factor, 
immunoglobulin M, Alpha1-antichymotrypsin, Villin and immunoglobulin G)165. 
Most of candidates biomarkers identified still need to be validated on large clinical 
cohorts; nevertheless the fact that many have been identified in different studies with 
different methods over the time increases the confidence in their ultimate utility. Among 
these are Beta 2 microglobulin 166-168, Zinc alpha2-glycoprotein (ZAG) 169, 170, 
Transforming growth factor-β1171, 172, interleukin 6173, CD90174, Engrailed-2 (EN2) 175, 
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Fibronctin 1168 and many other soluble factors and intracellular proteins involved in 
structural or metabolic functions. 
Engrailed-2 (EN2) is a transcription factor expressed in PCA but not in normal 
prostate tissues, and it was detected in urine by western blot and ELISA. Levels of EN2 
were 10.4-fold higher in PCA compared to controls. It showed sensitivity of 66% and a 
specificity of 88.2%, with AUC of 0.81 175. 
Beta-2-microglobulin (β2M) was reported as a potential marker of PCA 
aggressiveness. High levels of β2M were measured both in the serum167 and prostatic 
secretion176 of patients with metastatic PCA, and directly correlates with aggressive 
pathologic features in primary PCa specimens166. As a confirm, β2M was demonstrated to 
promote the epithelial-mesenchymal transition (EMT)177. 
Another candidate diagnostic biomarker for PCA is zinc alpha2-glycoprotein 
(ZAG). ZAG is a secreted protein, responsible for lipid degradation in adipocytes, 
expressed in blood, seminal fluid, urine, sweat and saliva. High levels of ZAG in seminal 
plasma are reported to be increased in PCA compared to healthy donors178. More recently, 
ZAG was reported to correlate also with PCA grade, with 1.3-fold increase in serum of 
Gleason score 7 PCA compared to Gleason score 5 179. This result was confirmed with 
ELISA in a larger cohort of samples, while IHC analysis demonstrated an inverse 
relationship; the possible explanation is the existence of two isoforms of ZAG in blood and 
seminal plasma.  
PTEN loss is associated with poor prognosis in metastatic androgen independent 
PCA. In order to identify new prognostic factors, 79 proteins have been measured in the 
sera of 57 patients with meta- static cancer under hormone ablative therapy. Target 
proteins were chosen based on their abundance after PTEN loss in in vivo models. A 
combination of ELISA and SRM methods was used. A panel of predictors composed of 
five proteins was determined: THBS1, CRP, PVRL1, MME, and EFNA5. The panel 
showed an AUC of 0.96  and 0.94 for cumulative hazard ratios at 12- and 24-months168, 180.  
An interesting comprehensive study diagnostic and prognostic biomarkers to 
differentiate indolent from aggressive PCA was performed using 4 pools of sera 
respectively from BPH, localized non-progressing cancer, localized progressing cancer and 
metastatic cancer168. After immunodepletion of the 14 most abundant serum proteins the 
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pools were analyzed by iTRAQ. A hierarchical clustering data analysis showed a high 
similarity between BPH and non-progressive cancer profiles, while the metastatic group 
clustered separately from all the rest. An increased level of eukaryotic translation 
elongation factor 1 alpha 1 (eEF1A1) was observed in progressing and metastatic cancer 
patients compared to BPH. Afamin and fibronectin were classified as potential diagnostic 
biomarkers for low-grade cancer, since a 1.4 fold higher level was observed in the non-
progressing cancer compared to the BPH. This study detected many already known PCA 
candidates biomarkers such as CRP, alpha-2-macroglobulin, zinc-alpha-2-glycoprotein, 
beta-2-microglobulin, fibronectin, and ceruloplasmin 181. 
Recently, exosomes appeared as a novel non-invasive source of 
cancer biomarkers182. Several type of tumor-specific molecules can be found in exosomes 
isolated from biological fluids. Proteomic profiling of endosomes from urine identified 
hundreds of proteins originating from several tissues, included from prostate 183-185. A 
recent study based on MS analysis compared 16 preoperative urine samples from PCA 
patients with 15 healthy controls, detecting 246 differentially expressed proteins186. 
Among these, 17 proteins showed sensitivity >60% at 100% specificity. TM256 protein 
had the highest sensitivity (94%) and when combined with a panel of other biomarkers, 
resulted to be able to fully differentiate PCA from healthy individuals. Another work based 
on immunoassays on exosomes extracted from urine to validate MS data, showed that 
flotillin 2, TMEM256, Rab3B and LAMTOR1 proteins have higher levels in PCA patients 
compared to healthy males. Flotillin 2 receiver operating characteristic curve showed AUC 
of 0.91, 88% sensitivity and 94% specificity187.  
Although all these findings require to be confirmed in larger cohorts of patients, 
these results support the feasibility of identifying highly sensitive and specific PCA 
biomarkers on urinary endosomes. 
4.3 Autoimmunity as a source of biomarkers for PCA 
Autoimmunity is the complex of immune responses developed by an organism 
toward its own proteins not recognized as self. Chemical exposures, infections and genetic 
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alterations are known causes of autoimmune diseases188. Cancer can also represent a cause 
of autoimmune response. Autoantibodies in cancer are thought to spontaneously develop 
due to antigens leakage from tumor tissue, production of new protein variants 
(neoantigens), or presence of proteins in the bloodstream in association with exosomes and 
microvescicles. Several studies confirm the usefulness of autoantibodies as biomarkers for 
diagnosis and prognosis of several different types of cancer46. Data about autoantibodies 
autoantibodies useful as biomarkers is still quite disperse in literature, but the interest on 
their application as biomarker candidates leaded to some effort in generating databases for 
the collection of all published autoantigens. One such database is AAgAtlas 1.0189. 
Autoimmunity has a polyclonal origin, where self-antigen presentation process is 
thought to be the same as for pathogenic antigens, with the immune system presenting the 
antigen as multiple and overlapping epitopes, each recognized by a different clone of 
lymphocytes190. The production of antibodies targeting TAAs represents a sort of 
“biological amplification” of protein biomarkers present at very low concentration in 
blood, even though sometimes the reactivity is not directly related to target concentration 
191.  
PCA is regarded as an immunogenic tumor. Literature reports quite some examples 
of autoantibodies useful in PCA diagnostic and prognostic process. An autoimmune 
signature able to distinguish PCA from controls with high specificity and sensitivity was 
published by Wang and colleagues already in the 2000192. Later on, another signature of 
174 antigens representing proteins related to cytoskeleton, nucleus and RNA-associated 
resulted to be reactive exclusively in PCA serum samples, while no reactivity was 
identified in controls191. Among the autoantibodies reported to be useful in PCA diagnosis 
are those toward cyclin B1193. Furthermore, autoantibodies have been reported to be useful 
also in defining PCA prognosis. The reactivity toward PSA, Her2194 and Fetuin-A195 is 
enhanced in late PCA stages compared to early stages. Moreover, the identification of 
autoantibodies in PCA correlates to treatment failure after androgen deprivation and 
radiation therapy196. Taken together these data suggest autoantibodies in PCA should be 
further investigated as a potential source of biomarkers for both PCA diagnosis and 
aggressiveness prediction. However, particular attention is needed in characterizing the 
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specificity of such reactivity, since epitope are targets of cross-reacting autoantibodies or 
polyreactive antibodies197-199.  
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5. Challenges in biomarkers discovery and validation 
 
Despite the wide number of hypothetical biomarkers identified by the application 
of proteomic technologies, only very few have been validated and implemented in the 
clinical practice. As George Poste stated in 2011: “The dismal patchwork of fragmented 
research on disease-associated biomarkers should be replaced by a coordinated 'big 
science' approach”200. 
The process to develop and validate a biomarker is hard, with only 3-5% of the 
biomarkers are transferred to the clinical practice201-203, and lab to lab variability present an 
important challenge in the process.  Standardized protocols and an appropriate training are 
needed to reduce such variability. Furthermore, the choice of the right sample set for 
discovery and validation, the storage protocols, the samples complexity and limited 
amount, the technology limitations, but also the statistical analysis approach are some of 
the main drawbacks to the biomarkers validation51. All these variables may be added to the 
already inconstant nature of sample composition among individuals, resulting in data 
misinterpretation. The following sections will discuss the more relevant sources of 
variation in a protein biomarker identification process.  
 
5.1 Study design  
 
The study design is the first critical aspect a researcher needs to reflect on when 
planning a study for biomarkers identification. A deep knowledge of biology, analytical 
platforms, biochemical properties and statistics is needed to provide reliable results out of 
a biomarkers study. This process requires an interdisciplinary team constituted by 
clinicians, investigators and statisticians.  
A clear biological question needs to be set and samples have to be selected 
accordingly, and avoiding any bias. Within the biomarkers research community there is 
widespread agreement that retrospective studies are less appropriate than randomized 
prospective studies, for which the hypotheses and analyses to be carried out are known in 
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advance204. However, under the appropriate circumstances, restrospective studies can also 
be very informative. One such case is the introduction of KRAS mutational screening in 
the decision making process for metastatic colorectal cancer treatment205.  
Untargeted screenings are useful when the research goal is to identify proteins or 
other molecules that are not already reported to be involved in a certain disease. Targeted 
analysis are more advisable for verification phase. 
Statistics is helpful in determining the number of samples necessary to reach a 
good statistical power, allowing to make valid conclusions out of the analysis results206, 207. 
When the research aim is to identify differentially expressed or activated proteins in 
different conditions, samples need to be matched for relevant variables such as 
demographic variables (e.g., age and gender) to be comparable. An appropriate assay 
needs to be chosen and the samples collection, storage and preparation have to be 
compatible with it. Possibly, the process should count for a good automation level, to 
avoid human errors. Samples should be randomized to avoid any bias due to sample 
position or time-delay in the analysis. Including replicates in the analysis is also essential 
to guarantee statistical power and evaluate technical variation. Replicates are intended on 
different levels and the number of replicates depends on sample availability and on the 
assay platform used for the analysis. More analytical repetitions of the same sample can be 
included in an experimental run, or the entire experiment can be repeated on a different 
time with the same or modified layout. 
Beside this, every analytical platform and assay have limits that inevitably affect 
the output data, and therefore need to be considered during the study design. The study 
design process is therefore complex and have the aim to face and give answer to a research 
question, by predicting and minimizing all the possible variables that could affect the 
results. The thoroughness in this phase is an essential requirement to guarantee the success 
of the research. 
 
5.2 Pre-analytical variables  
 
Biological samples are very complex matrices, which typically contain many 
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components, such as cells, proteins, nucleic acids, lipids, and metabolites. Moreover, the 
inter-individual heterogeneity – characterized by genetic diversity – makes the scenario 
very complex, challenging even more the identification of new biomarkers. If this intrinsic 
variation cannot be avoided, at least the procedures followed for samples collection, 
handling and storage need to be standardized across the different laboratories, and 
guidelines need to be established for high-quality translational research200. 
Guidelines change depending on the sample type, and on the type of assay. The 
mechanical process for collection causes a trauma to the sample and its components. 
Indeed, the cells in a tissue biopsy are alive and adapt to the trauma of excision, change of 
temperature, ischemia, and hypoxia208, 209. Such events induce modifications in pathways 
involved in the response to stress, in DNA repair system, and in protein 
phosphorylation/dephosphorylation in response to stress210. Biopsies can be collected 
intra-surgery or as image-directed needle biopsies. It is important to stop all cellular 
processes and stabilize proteins and PTMs in tissue samples to avoid imbalances of tissue 
molecular structure. The gold standard for preservation is represented by formalin-fixed 
and paraffin-embedded tissue (FFPE), which is a widely used method for tissue 
preparation for IHC analysis211. However, the slow process of tissue permeation by 
formalin causes a significant degradation of both proteins and nucleic acids212. To avoid 
these degradation processes, new types of fixative were introduced that optimize the 
protein and PTMs preservation and maintain the tissue morphology; among these are 
optimal cutting temperature (OCT) compound210 and the one-step biomarker and histology 
preservative (BHP)213. Tissue fixation with OCT and BHP is followed by snap-freezing in 
liquid nitrogen. The delay between tissue excision, pathologic examination and sample 
storage is a major source of variation causing changes in proteome composition. The entire 
procedure requires from 30 minutes to several hours depending on organizational factors 
(e.g., laboratories and surgery rooms location, availability of a pathologist, and the number 
of concurrent cases), and during this time temperature fluctuation occurs that causes 
variations in the molecular network. The specimen size also represents a source of 
variation. In fact, bigger samples require longer time to allow the fixative to penetrate the 
tissue in depth and block the degradation processes214.  
When analyzing body fluids, other variables should be considered. For blood and 
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its derivatives (e.g., plasma and serum), the delay time between sample centrifugation and 
freezing does not affect the majority of the proteins215, 216; but for some, such as 
interleukines, chemokines and growth factors there can be a substantial variation217. Also, 
the composition of serum and plasma, the used collection tubes, and anti-coagulants can 
cause alterations in proteome composition of the sample218, 219.  
Other studies were developed to characterize the stability of stored samples, 
showing that repetitive freeze-thawing cycles influence the proteome composition more 
than long-term storage at -70 C220, 221. Freeze-thawing cycles are critical for the stability of 
the great majority of proteins, but seem not to affect much immunoglobulins stability.  
It appears clear that standardized procedures for samples collection and storage are 
essential to guarantee high quality data production for the identifications of biomarkers. 
 
5.3 Analytical variables  
 
The outcome of an analysis that aims to detect and measure proteins that can 
possibly be useful as biomarkers strongly depends on sample preparation, and on the assay 
limits in terms of sensitivity and specificity.  
Biomarkers are usually detected at low concentration, and identified in very 
complex matrixes. For these reasons the detection methods have to be high specific and 
sensitive, while the sample needs to undergo to a preparation that can be a further source 
of variation.  
Tissues are constituted by many different cell types (e.g., fibroblasts, nerve cells, 
endothelial cells, infiltrating lymphocytes, epithelial cells, etc) that cross-talk with each 
other, and coordinate to sustain tumor growth and proliferation. Tissue heterogeneity 
represents a significant obstacle for identifying protein biomarkers specific for malignant 
cells. Indeed, different individuals with the same type of cancer, and even different 
biopsies of the same tumor, can have a peculiar distribution and different amount of each 
cell type. For this reason, upfront cellular enrichment is often needed to disassemble this 
complex tissue ecosystem and analyze the signaling network in different cell 
subpopulations separately111, 123. Over the years, many laboratories have coupled molecular 
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analyses with upfront LCM or cell sorting222-224. Another source of variation when 
working with tissue is the protein extraction process. Protein degradation or changes can 
occur during tissue lysis. It is therefore advisable to inhibit proteases, phosphatases and 
kinases at all phases of the analysis, from tissue collection to lysis. A variety of proteases 
and phosphatases inhibitors are commercially available, and can be applied to tissue 
lysates or tissue slides during LCM process, to stabilize the proteome. 
On the other hand, the wide concentration range of proteins in blood, which spans 
up to 12 orders of magnitude, present a critical problem in the identification of blood 
biomarkers. 225. Biomarkers in blood derive from tissues, pass through the endothelial 
barrier, and reach the circulation where they are diluted in a high amount of bio-fluid. To 
be able to detect low concentrated proteins, samples undergo to preparation such as 
depletion, fractionation, enrichment, enzymatic digestion or heating226. These can cause 
sample alteration in composition, and the analysis is further complicated by the fact that 
low molecular weight (LMW) proteins may exist in complexes with high molecular weight 
(HMW) and high abundance proteins such as albumin and immunoglobulins that are often 
discarded and removed a priori by depletion techniques227, 228. A possible way to 
overcome this issue is the introduction of hydrogel nanoparticles to enrich low abundant 
proteins 229, 230. 
Sample handling and preparation helps in detection of proteins and can be different 
for different sample type and application. However, this might alter the protein 
composition in such extent that disease related profiles cannot be found. To reduce the 
impact of manual handling, new one-step sample preparation methods are developed231.   
Affinity-based methods strictly depend on the characteristics of the used binder. 
Antibodies need to have high sensitivity and specificity, and need to be validated. 
Antibodies are known to perform differently in different applications, therefore a result 
obtained with an array can frequently not being verified using other immunoassays (e.g., 
IHC). On the other hand, antigen-based arrays are also subjected to variation due to 
antigens conformation of different platforms. Antigens can have different length and can 
fold causing linear epitope inaccessibility or generation of conformational epitopes 
different from those of the native protein232.  
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Finaly, another important source of variation is due to human error. Methods for 
biomarkers measurement should be highly robust, and standardized for dilution linearity, 
precision and intra- and inter-assay reproducibility. Analytically, in modern high-
throughput laboratories automation is essential233, 234.  
 
5.4 Post-analytical variables  
The post-analytical phases in the biomarkers evaluation process involves data 
analysis procedures, including normalization and interpretation. Post-analytical errors 
might affect biomarkers performance as much as pre-analytical and analytical variable do. 
Most of the times, variables in biology context are continuous, raising the problem to 
define cut-offs for clinical tests. Also, continuous data tend to be less reproducible than 
dichotomous parameters. For these reasons, a standardization is needed also for data 
analysis, and it can be reached only through a tight collaboration between clinicians, 
investigators and statisticians51. When working with –omics data it is necessary to be even 
more careful in data handling, due to the high amount of endpoints. Once generated, data 
undergo quality controls to inspect technical variation. One basic control is the evaluation 
of the coefficient of variation (CV) for the technical replicates included in the assay. 
Another step is the evaluation of data distribution using histograms, scatterplots or 
principal component analysis (PCA)235. When data is influenced by technical artifact, 
normalizations are needed. In general, normalization is used to adjust values so that they 
can be compared across the samples. The choice of a  normalization method is critical 
because it can deeply affect the results of the analysis236. The most common methods for 
protein microarrays are probabilistic quotient normalization (PQN), variance stabilizing 
normalization, cyclic loess and robust linear model normalization 237-239. Caution is also 
needed while removing outliers, since in many cases what it’s defined as outlier could 
have a biological meaning. Furthermore, another issue is setting a clear cut-off for where 
outlier behavior starts. After data pre-processing, several statistical tools are available to 
compare protein expression or activation data deriving from microarray analysis between 
samples and different conditions. Among these are t-test, Wilcoxon rank sum test, linear 
models, fisher exact test, and others. Each of these tests has to be chosen based on intrinsic 
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properties of the data set, such as t-test, used only on normally distributed data. Statistical 
test measures the probability there is no difference between the compared groups. This 
measure is given by p-values. When p-value is small (p<0.05) there is high probability that 
the difference is real. When comparing microarray data, many statistical tests are run in 
parallel for each of the tested proteins. If the p-value cut-off for significance is 0.05, this 
means that when testing 1000 proteins by random chance alone we would expect 50 false 
positives. Bonferroni correction or false discovery rate (FDR) can be used to reduce false 
positives, but sometimes they can be too conservative and cause discard of true 
discoveries240. 
For each step within data analysis, a good visualization is helpful for result 
interpretation, especially with high-dimentional data. After normalization, histograms, 
boxplots and scatterplots can help for visualizing changes in data distribution. 
Unsupervised hierarchical clustering analysis and heatmaps can be used to explore 
patterns. After analysis of differential expression, volcano plots can show the significance 
and fold-change, and receiver operating characteristic (ROC) curve can visualize the 
relation between sensitivity and specificity of a classification. 
There is a need for specifically designed database for protein microarray data 
archiving and sharing, and tailored standards for data processing and analyzing. Some 
examples are now available and likely will be implemented in the future, allowing for 
development of standard data processing pipeline241. 
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6. Current investigation 
As the title suggests, the work presented in this thesis is based on the profiling of 
PCA tissue and blood samples by using affinity proteomics platforms such as RPPA, 
antigen and peptide arrays. In the field of PCA research, the major lack is represented by 
the absence of biomarkers able to define the prognosis of patients. PCA diagnosis has 
shown substantial improvements in the last decade, while the wide spectrum of disease 
outcome that ranges from indolent disease to aggressive forms makes it urgent to introduce 
in the clinical practice new biomarkers to predict the patient prognosis and chose the best 
type of treatment. This will allow to early identify aggressive forms that need radical 
treatment, and at the same time to avoid heavy side-effects generated from overtreatment 
of patients with indolent PCA. The aim of the work here presented is to apply proteomic 
platforms, such as antigen planar and bead-based arrays, peptide bead arrays and RPPA, to 
characterize prostate cancer samples and to possibly identify new biomarker candidates in 
tissue and/or blood. As previously mentioned, proteins are the functional units of the cell, 
and the basis for communication between cells. Tissue cells can release proteins into the 
body fluid circuit by secretion or leakage, in response to stimulation or damage. Proteins 
are therefore the ideal biomarkers for several diseases, and also for PCA.  In Paper I we 
wanted to unravel the mechanisms of communication that underlie PCA development and 
progression by disassembling tissue samples collected from PCA and adjacent normal 
tissue in its stromal and epithelial compartments using LCM technology, and profiling 
them separately using RPPA. Particular emphasis was given to the measurement of protein 
phosphorylation, to allow a picture of the activation status of important pathways expected 
to be involved in PCA driving processes. Tissue samples have the great advantage of 
giving a clear picture of the tumor molecular status. However, tissue samples can be 
obtained only through invasive procedures, therefore making them precious and limited. 
The identification of biomarkers in plasma/serum would allow avoiding such invasive 
procedures and providing higher amount of sample. A drawback in the use of plasma as a 
source of biomarkers is the low concentration of tissue proteins, requiring high sensitive 
methods to be detected. To some extent, cancer autoimmunity could be considered as a 
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natural amplification for low concentrated proteins in blood, even though the reactivity 
toward a certain protein is not always directly correlated to its expression levels or 
concentration. In Paper II we aimed to broadly screen plasma and serum samples of PCA 
patients and controls to study their autoimmune repertoire, and to identify autoimmune 
markers for the definition of PCA prognosis. To this purpose we applied antigen arrays 
from the HPA project collection, together with peptide arrays.  
The most significant findings and the experimental design for each of the two 
presented papers are reported in the following sections. For further details we refer to 
original papers, which are not included in this thesis for copyright reasons. A discussion on 
faced challenges and perspectives is also present.  
 
6.1 Paper I: Dissecting the PCA epithelium-stroma 
molecular architecture in tissue samples by using LCM and 
RPPA  
This paragraph summarizes methods and results of a research study carried on by the author of this thesis´ 
and collaborators. The research was published on Molecular Oncology in October 2016 as an original 
article that can be referred to for more details. Reference:  Pin E, Stratton S, Belluco C. A pilot study 
exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser 
capture microdissection and reverse phase protein microarray. Mol Oncol. 2016. doi: 
10.1016/j.molonc.2016.09.007. [Epub ahead of print] 
 
Understanding the cross-talk between the tumor and stroma compartments in tissue 
is essential for identifying novel biomarkers to personalize and optimize the treatment of 
PCA patients, and in general for patients affected by solid cancers. This study tested the 
feasibility of using LCM and RPPA combination as a powerful workflow for unrevealing 
the signaling architecture of the tumor-stroma cross-talk by using PCA as a model. 
Biopsies from tumor and the adjacent normal-appearing tissue were collected from 18 
PCA patients diagnosed as Gleason score 6-7. The choice of this subgroup of patients is 
justified by the urgency to define the prognosis of Gleason score 6-7 PCA patients. 
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Biopsies were embedded in OCT and snap-frozen within few minutes from collection to 
guarantee the best possible preservation of proteins and phosphorylations. After cutting the 
tissue in thin sections, the tumor epithelial cells, the normal-appearing epithelium, the 
stroma adjacent to the tumor epithelial cells, and the stroma surrounding the normal-
appearing epithelium were isolated using LCM and separately profiled by RPPA platform. 
The choice to print stroma and epithelium samples onto different arrays and analyze them 
separately was due to the limited amount of microdissected material (<10000 cells per 
compartment), and to the fact that each compartment expresses specific proteins or showed 
activation of different pathways. For instance, the HER family proteins and their activation 
status were analyzed only in the epithelial compartment, while proteins such as Caveolin, 
the MMPs, and markers of immune activation like Zap70 Y319/Syk Y352 are known to be 
more involved in stromal activities, and were therefore analyzed only in this context. 
Beside these, proteins ubiquitous across different cell types, such as the members of the 
AKT-mTOR pathway, were analyzed both in the epithelium and stroma compartments. 
The expression or activation status of each target was compared between tumor and its 
normal appearing counterpart. Also, the correlation between targets was evaluated within 
and between compartments. This approach allowed the rebuilding of the molecular 
architecture of each compartment, and clarifying the interconnection between stromal and 
epithelial compartments.  
All the endpoints found to be differentially expressed/activated between the normal 
and tumor compartments are summarized in Table 1. As expected, our results showed a 
decrease in the PTEN expression (p=0.01) and activation (p=0.01) in PCA epithelial 
compartment. Also, PTEN expression/activation showed a negative correlation with Akt 
S473 in both tumor and normal-appearing epithelium. The association was less strong in 
the malignant lesion, likely as a result of PTEN loss and other signaling derangements 
affecting the Akt pathway (Fig. 4). In agreement with the PTEN loss, we identified other 
events such as the overexpression of the anti-apoptotic protein Survivin and the 
suppression of Stat3 signaling through the modulation of the IL8-Stat3 signaling pathway. 
The tumor epithelium showed also an increase in B-Raf S445 and AR S650 
phosphorylation compared to its normal-appearing counterpart, in agreement with tumor 
progression, and development of castration resistant PCA (Tab. 1).  
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Table 1. List of proteins/phosphoproteins that were statistically different between the tumor and 
normal-appearing tissue (p < 0.05). Panel A lists proteins that were statistically different between the 
tumor and normal-appearing epithelium. Panel B contains a list of proteins that were statistically 
different between the stroma surrounding the tumor and normal-appearing epithelium. For each 
analyte the trend in the tumor compartment compared to the normal counterpart, RPPA mean 
intensity values and 95% confidence interval (CI), percentage change of protein expression or 
activation in the tumor compared to the normal, the test performed, and the p-value are reported. 
 
   * p-value calculated based on two-sample t-test; **   p-value calculated based on Wilcoxon rank sum test 
 
Regarding the stroma compartment, increased levels of IL-8, Egr-1, TIMP-2, and 
the hyperactivation of MEK, Erk, Akt and its downstream substrate eNOS were detected in 
the malignant compared to the normal-appearing counterpart (Tab. 1). These findings are 
in agreement with previous studies, and connecting them allowed us to rebuild the 
molecular cascade of events that leads PCA to become androgen-independent by the AR 
activation due to IL8 produced by stroma (Fig. 5).  
Unexpectedly, our data also showed an increase in the activation level of the 
inflammatory molecules Stat3 Y727 and Stat5 Y694 along with different members of the 
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Smad family, and the RTKs ErbB2 Y1248 and ErbB3 Y1289 in the normal-appearing 
epithelim 
 
Figure 4. Correlation matrices of the different cellular compartments. In a color-coded scale from blue 
(low) to high (red) are represented the correlation coefficients for each pair of targets included in the analysis 
for A) tumor epithelium, and B) normal-appearing epithelium. 
 
 
Figure 5. Protein network activation in PCA tumor microenvironment. The scheme represents selected 
proteins and phosphoproteins found to be differentially activated/expressed in the tumor epithelium and 
nearby tumor associated stroma. 
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To us, the explanation lays on the field cancerization effect242, a biological process 
where morphologically normal-appearing areas close to the tumor were found to carry 
genetic alterations and deranged molecular structure; this is in agreement with the multi-
step theory that attributes the clonal expansion, and the subsequent tumor development, to 
the accumulation of genetic alterations that can already occur in a still morphologically 
normal-appearing tissue. Supporting this, our results showed that the stroma surrounding 
the normal-appearing epithelium has a large number of strong positive correlations 
between targets involved in the immune response but also in the remodeling processes of 
extracellular matrix (e.g. Caveolin, MMP-9, IRAK1, Jak2, TGFb, TIMP-3, Zap70, 
Podoplanin) (Fig 6). 
 
 
 
Figure 6. Correlation matrices of the normal-appearing stroma. In a color-coded scale from blue (low) 
to high (red) are represented the correlation coefficients for each pair of targets included in the analysis. 
 
The correlation analysis of targets identified highly differential changes in the 
inflammatory/immune-response between the four different compartments. In the normal-
appearing epithelium and surrounding microenvironment known feedback mechanisms 
regulating immuno-surveillance were more extensively maintained compared to the 
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malignant counterpart. The stroma surrounding the tumor cells showed a negative 
correlation between the IL-10 secretion and the lymphocyte activation status. IL-10 has 
also emerged as a major interaction node between epithelium and stroma of the malignant 
PCA tissue (Fig. 7).  
 
 
 
 
Figure 7. Correlation analysis of tumor epithelium and mtched stroma. The diagram 
shows only correlations with coefficient > or equal to 0.75. 
 
Based on the reported results, the workflow proposed in our study allowed us to 
explore the molecular network regulating the cross-talk between tumor and 
microenvironment during PCA growth and progression. Even if based on a low number of 
samples and limited by the field cancerization effect - which restricts our comparison to 
the signaling network of tumor cells and a normal-appearing but clearly already affected 
epithelium - our results indicate the feasibility of combining LCM and RPPA for 
separately profiling and evaluating the molecular architecture and cross-talking of 
epithelial and stromal compartments, needing very little clinical material.  Further analyses 
on a larger number of samples are required to confirm our findings.  
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6.2 Paper II: Profiling the autoimmune repertoire in PCA by 
using planar and bead-based antigen and peptide arrays  
This paragraph summarizes methods and results of a research study carried on by the author of this thesis´ 
and collaborators. The research was published on the Journal of Proteome Research in October 2016 as an 
original article that can be refered to for more details. Reference:  Pin E, Henjes F, Hong MG. Identification 
of a novel autoimmune peptide epitope of prostein in prostate cancer. J Proteome Res. 2016. DOI: 
10.1021/acs.jproteome.6b00620 [Epub ahead of print]. 
 
Blood deriving biomarkers are desirable due to the less invasive sampling 
procedures, and the higher amount of available sample. In this study, we profiled the IgG 
repertoire of 589 plasma and serum samples from PCA patients with early and late-stage 
disease plus 20 controls (Tab. 2), to identify new potential autoimmune biomarkers for 
improving the definition of patient prognosis. The investigation was divided into three 
phases where we also combined planar antigen array, bead-based array and peptide arrays 
to validate our results (Fig. 8).  
 
 
Figure 8. Study experimental design. The diagram represents the three phases in which the study was 
divided. A first untargeted screening phase was run on planar antigen arrays on 80 samples and testing 
reactivity toward 3768 protein fragments from the HPA collection. A selection of 161 antigens resulted 
reactive in phase 1, plus 71 additional targets selected from literature were included in phase 2. Protein 
fragments were coupled on magnetic beads to create a suspension bead antigen array. Reactivity toward 
these antigen was tested in 550 PCA plasma samples from early and late stage disease patients. Prostein 
representing fragment was highly reactive at late stages compared to early and was selected for further 
analysis to test the specificity of reactivity and to map the epitope.  
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Table 2. Clinical Data fof PCA Patients Included in Untargeted and Targeted Screening Phasea 
 
a Clinical information are marked with (*) when the number of individuals did not correspond to total due to 
lack of data. Percentages are calculated considering only patients with available information. The Table does 
not include the 20 control subjects, for which no clinical information was available but age (66.6 ± 9.4). 
 
A first broad untargeted screening phase was run with 80 age-matched samples 
divided in 20 healthy controls, 40 low stage PCA and 20 high stage PCA (from set 1 and 2 
, Tab. 2). Using planar antigen microarrays produced within the HPA project, we tested the 
reactivity toward 3768 antigens, representing 3363 unique proteins. A high heterogeneity 
of reactivity was identified across the samples, characterized by a broad intensity range, 
with many antigens showing high intensity only in one single sample (Fig. 9).  
Considering the high heterogeneity, a cut-off for antigens selection was set per 
sample, and by combining both intensity and frequency. Antigens with the highest 
intensities were considered valuable of inclusion in the second targeted screening phase 
only when a minimum of 2 samples passed the more stringent used cut-off (median + 250x 
MAD cut-off), while for antigen with lower intensity a higher frequency (minimum 10 
reactive samples) was required for selection.  
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Figure 9. Heterogeneity of reactivity. (A) Example of IgG intensity profile 
for 1 samples over all 3768 antigens included in the untargeted screening 
phase. Red peaks represent antigens passing the cut-off and toward which IgG 
were reactive. (B) A large interindividual variation of reactivity profiles was 
observed, with most antigens recognized in single individuals only. 
 
 
From this selection, 161 antigens were included in the second phase of the 
investigation. Beside these, other 71 antigens were selected representing interesting 
proteins from literature. In total, 201 unique proteins were included in the targeted 
screening phase. Reactivity toward the 232 protein fragments was evaluated using bead-
based antigen arrays in 550 plasma samples collected from PCA cases at diagnosis (set 2; 
Tab. 2). Patients were classified in high T-stage (T3-T4) and low T-stage (T1-T2), and in 
high Gleason score (>7), median Gleason score (7) and low Gleason score (<7). Statistical 
analysis revealed that 3 antigens where more reactive at later stage of the disease, and they 
were representing IGFBP2, TBP and SLC45A3 - alias prostein – proteins (Tab. 3).  
 
 
  50 
Table 3. Frequencies and Statistical Analysis Results for Antigens Identified To Be Differentially 
Reactive based on T-Stage and Gleason Score comparisons 
Gene Uniprot ID 
Frequency of Reactivity 
%(N) 
   
High 
Group* Low Group* 
Fisher Exact 
Test** t-test*** 
High vs Low T-stage         
IGF2BP2 Q9Y6M1 33 (14) 18 (91) 0.025 0.18 
SLC45A3 Q96JT2 26 (11) 14 (71) 0.044 0.49 
High vs Low Gleason score       
SLC45A3 Q96JT2 27 (9) 10 (10) 0.044 0.35 
TBP P20226 21 (7) 5 (5) 0.016 0.39 
* When the percentage and number of samples does not match the numbers reported in Tab. 1, it is due to 
exclusion of some samples from the analysis for technical criteria. ** Comparison of reactivity frequencies 
between the two groups. *** Comparison of mean of intensities between the two compared groups. 
 
 
 
Among these 3 proteins we selected prostein, and analyzed its reactivity in deeper 
because it was confirmed to be more reactive at late stages of PCA both comparing high 
versus low T-stage and Gleason score (Tab.3 and Fig.10).  
Also, prostein expression is restricted to prostate cells, making it a perfect PCA 
biomarker candidate. Further analyses were performed to identify the reactive epitope and 
test the specificity of this reactivity. Autoimmunity is complex, and often polyreactive 
antibodies or antibodies with specificity for other proteins with high homology could 
cross-react with an epitope. Being able to discriminate if the reactivity we identified is 
specific for prostein is essential for defining its role as a candidate biomarker. For this 
reason, both male and female samples collected pre-diagnosis were tested for reactivity 
toward the prostein antigen. Reactivity in men pre-diagnosis was identified at levels 
similar to very early stage PCA, possibly explained by the fact that prostein is expressed in 
both normal prostate and PCA or due to antibodies cross-reacting with the fragment. 
Female samples showed a median of signal slightly lower than men prediagnosis. 
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Figure 10. SLC45A3/Prostein structure and reactivity. (A) Secondary structure shows 
that prostein is a transmembrane protein with 11 transmembrane domains. Reactive antigen 
(red; aa 412−477) are localized in intracompartmental domains. (B) Linear model showing 
association between the reactive prostein antigen MFI and the tumor stage. ● = reactive 
samples. P-value for Anova test is reported in the graph. 
 
An epitope mapping analysis using bead-based array with overlapping 15mer peptides to 
cover the whole prostein 66 aminoacids fragment sequence, showed that both men and 
women prediagnosis and PCA samples share the same epitope. The 9 aminoacid length 
epitope with sequence GPKPGAPFP covers the prostein sequence from aminoacid 434 to 
442, in the C-terminal region (Fig. 11).  
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Figure 11. Prostein epitope identification. (A) Dot plots showing the MFI mean detected in 
reactive (R; N = 40), nonreactive (NR; N = 189) and female (F; N= samples, for epitope mapping 
using 15mers with 13 aa overlap to the next one. P1 was excluded from the analysis due to 
technical reasons. (B) Sequence of each of the statistically different peptides identified with the 
epitope refinement analysis using 15mers with 14 aa overlap to the next one. The epitope is 
highlighted in orange. 
 
The high concentration of prolines, which are 4 out of 9 aminoacids, makes the 
epitope a target for natural polyreactive antibodies, which could explain the reactivity 
identified in female samples. Beside this, the reactivity in women could be explained also 
by the hypothetical presence of autoantibodies directed toward epitopes of TGIF2 which 
showed a sequence with 78% homology to prostein epitope. In parallel, also part of the 
men reactivity could be aspecific due to polyreactive antibodies, antibodies toward TGIF2, 
and also toward TMEM79, another prostate specific protein containing a sequence with 
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78% homology to the identified prostein epitope. In conclusion, our study demonstrates 
once again the high level of complexity of the immune system, and that it can be a source 
of biomarkers for PCA. These results also show that the deconvolution of such complexity 
is essential to identify useful and specific autoantibodies biomarkers. A limitation of our 
study is the use of protein fragments. This leads to lack of information about the presence 
of other epitopes on the same protein. Still, the availability of thousands of protein 
fragments is a unique resource for autoimmunity analysis. We believe that our approach 
based on cross-platform validation using antigen and peptides, planar and bead-based 
arrays, and complemented with bioinformatics analysis, could be a comprehensive and 
solid approach for deep characterization of the autoimmune repertoire. 
 
6.3 Conclusions and future perspectives 
The work here presented is based on profiling of proteins, phosphoproteins and 
autoantibodies within PCA by means of microarray technology, with the aim to identify 
new biomarkers. Thanks to their high sensitivity and mid to high throughput, both FPPA 
and RPPA are suitable for profiling biological samples and identifying biomarkers or 
molecular profiles related to a disease status. In Paper I, profiles related to proteins and 
phosphoproteins were evaluated in PCA tissue samples from patients with medium 
Gleason score (6-7). In particular, LCM and RPPA were coupled to separately profile the 
stroma and epithelium of both cancer and the surrounding normal-appearing epithelium, 
with the aim to rebuild the molecular structure of each compartment and study the 
epithelium-stroma cross-talking. Even though the number of enrolled patients was limited, 
the statistical analysis allowed to identify significant variations and correlations between 
targets in different compartments. Thanks to the high-sensitivity of RPPA, the expression 
and/or activation status of many targets was analyzed even when very limited amount of 
sample was available. Taken together, our analysis allowed to reveal differences in the 
activation of pathways between the different compartments. Beside differences, the study 
allowed also to rebuild a network that could explain PCA progression in Gleason score 6-7 
patients by epithelium-stroma cross-talk.   
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In Paper II we identify a new IgG reactive epitope of prostein in PCA patients 
correlating with the stage of the disease. A general individual variation was observed for 
autoimmunity reactivity in PCA patients. This is in agreement with what present in 
literature, where reactivity toward human proteins are reported also for healthy individuals, 
and the majority of antigens show reactivity in a single individual or few individuals. 
Autoantibodies reactive toward the same antigen in many individuals are rare, making 
difficult to identify common patterns related to a disease. Beside this, cross-reacting 
autoantibodies or polyreactive antibodies can recognize the same epitope making the 
picture more complex, as highlighted also by our results on prostein. Reactivities are 
identified also in healthy samples, suggesting that an analysis of the baseline status in the 
general population is needed to profile autoantibodies in absence of symptoms, and 
possibly clean or normalized results in pathological conditions. 
The data presented in this thesis provides a robust framework for protein profiling 
in tissue, and autoantibodies profiling in plasma in the context of PCA. Beside this, our 
data put some new insights on the molecular processes underlying PCA development and 
progression. The proposed workflows are based on careful evaluation of all the variables 
that could influence the results, from study design to data analysis. Our findings need to be 
validated in future studies involving a larger number of samples collected independently, 
hopefully contributing to increase knowledge, and optimizing the treatment of PCA. 
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